Regentis Biomaterials Ltd (RGNT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2001 | 12-2000 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 7,378 | 229 | 345 | N/A | N/A |
| Other current assets | 240 | 253 | 15 | 680 | 3,330 |
| TOTAL | $7,618 | $482 | $360 | $680 | $3,330 |
| Non-Current Assets | |||||
| Investments And Advances | 0 | 0 | 0 | 490 | 620 |
| Other Non-Current Assets | 0 | 0 | 0 | 2,570 | 6,030 |
| TOTAL | $N/A | $N/A | $N/A | $3,060 | $6,650 |
| Total Assets | $7,618 | $482 | $360 | $3,740 | $9,980 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,197 | 4,945 | 210 | 13,150 | 5,910 |
| Accounts payable and accrued liabilities | 1,677 | 1,383 | 2,929 | 5,100 | 3,180 |
| Accrued Expenses | N/A | N/A | N/A | 1,190 | 2,360 |
| Other current liabilities | N/A | 160 | N/A | 0 | 320 |
| TOTAL | $2,874 | $6,488 | $3,139 | $21,910 | $11,770 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 35,098 | 43,126 | 2,550 | 22,030 |
| TOTAL | $N/A | $35,098 | $43,126 | $13,100 | $27,290 |
| Total Liabilities | $2,874 | $41,586 | $46,265 | $35,010 | $39,060 |
| Shareholders' Equity | |||||
| Common Shares | N/A | N/A | N/A | 10,610 | 10,610 |
| Retained earnings | -55,794 | -42,146 | -46,947 | N/A | N/A |
| TOTAL | $4,744 | $-41,104 | $-45,905 | $10,610 | $10,610 |
| Total Liabilities And Equity | $7,618 | $482 | $360 | $45,620 | $49,670 |